IT1234215B - Forma di dosaggio per il trattamento di malattie cardiovascolari - Google Patents

Forma di dosaggio per il trattamento di malattie cardiovascolari

Info

Publication number
IT1234215B
IT1234215B IT8867880A IT6788088A IT1234215B IT 1234215 B IT1234215 B IT 1234215B IT 8867880 A IT8867880 A IT 8867880A IT 6788088 A IT6788088 A IT 6788088A IT 1234215 B IT1234215 B IT 1234215B
Authority
IT
Italy
Prior art keywords
treatment
dosage form
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
IT8867880A
Other languages
English (en)
Other versions
IT8867880A0 (it
Inventor
Atul Davdatt Ayer
David R Swanson
Anthony L Kuczynski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IT8867880A0 publication Critical patent/IT8867880A0/it
Application granted granted Critical
Publication of IT1234215B publication Critical patent/IT1234215B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT8867880A 1987-10-02 1988-09-30 Forma di dosaggio per il trattamento di malattie cardiovascolari IT1234215B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (2)

Publication Number Publication Date
IT8867880A0 IT8867880A0 (it) 1988-09-30
IT1234215B true IT1234215B (it) 1992-05-06

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8867880A IT1234215B (it) 1987-10-02 1988-09-30 Forma di dosaggio per il trattamento di malattie cardiovascolari

Country Status (22)

Country Link
US (1) US4816263A (it)
JP (1) JP2590235B2 (it)
KR (1) KR950010151B1 (it)
AT (1) AT402689B (it)
AU (1) AU615215B2 (it)
BE (1) BE1001101A5 (it)
CA (1) CA1317550C (it)
CH (1) CH677609A5 (it)
DE (1) DE3833282C2 (it)
DK (1) DK175564B1 (it)
ES (1) ES2011120A6 (it)
FI (1) FI92554C (it)
FR (1) FR2622798B1 (it)
GB (1) GB2210266B (it)
IE (1) IE61862B1 (it)
IT (1) IT1234215B (it)
LU (1) LU87351A1 (it)
NL (1) NL194748C (it)
NO (1) NO176466C (it)
PT (1) PT88618B (it)
SE (1) SE503471C2 (it)
ZA (1) ZA887362B (it)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
JP4216713B2 (ja) * 2001-06-11 2009-01-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
AU2004227995B2 (en) * 2003-03-31 2010-06-03 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of GABA analogs
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
MXPA06002731A (es) * 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
US8114909B2 (en) * 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
JP4938771B2 (ja) 2005-06-20 2012-05-23 ゼノポート，インコーポレーテッド トラネキサム酸のカルバミン酸アシルオキシアルキルプロドラッグ、合成法、および使用
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
EP1928450A2 (en) * 2005-08-26 2008-06-11 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
ES2456674T3 (es) 2006-05-26 2014-04-23 Signature Therapeutics, Inc. Liberación controlada de opioides fenólicos
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
AU2007332904A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of GABA analogs for treating diseases
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2621282B1 (en) 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
IE61862B1 (en) 1994-11-30
DE3833282C2 (de) 1997-02-13
KR890006218A (ko) 1989-06-12
LU87351A1 (fr) 1989-04-06
ATA242288A (de) 1996-12-15
PT88618B (pt) 1993-07-30
IE882960L (en) 1989-04-02
CH677609A5 (it) 1991-06-14
ZA887362B (en) 1989-06-28
SE503471C2 (sv) 1996-06-24
DE3833282A1 (de) 1989-04-20
FI92554C (fi) 1994-12-12
FR2622798B1 (fr) 1993-10-15
NL194748C (nl) 2003-02-04
IT8867880A0 (it) 1988-09-30
SE8803486D0 (sv) 1988-09-30
CA1317550C (en) 1993-05-11
NO884259D0 (no) 1988-09-27
NL194748B (nl) 2002-10-01
FR2622798A1 (fr) 1989-05-12
DK545088D0 (da) 1988-09-29
NO176466B (no) 1995-01-02
DK545088A (da) 1989-04-03
GB2210266B (en) 1991-07-24
PT88618A (pt) 1989-07-31
SE8803486L (sv) 1989-04-03
NO176466C (no) 1995-04-12
AU615215B2 (en) 1991-09-26
GB8822852D0 (en) 1988-11-02
AU2293888A (en) 1989-04-06
DK175564B1 (da) 2004-12-06
ES2011120A6 (es) 1989-12-16
JPH01113316A (ja) 1989-05-02
NL8802401A (nl) 1989-05-01
US4816263A (en) 1989-03-28
FI884526A0 (fi) 1988-09-30
JP2590235B2 (ja) 1997-03-12
NO884259L (no) 1989-04-03
BE1001101A5 (fr) 1989-07-11
AT402689B (de) 1997-07-25
GB2210266A (en) 1989-06-07
FI92554B (fi) 1994-08-31
FI884526A (fi) 1989-04-03
KR950010151B1 (ko) 1995-09-11

Similar Documents

Publication Publication Date Title
IT1234215B (it) Forma di dosaggio per il trattamento di malattie cardiovascolari
IT8447675A0 (it) Composti farmacologicamente attivi per il trattamento di affezioni gastrointestinali e procedimento di preparazione
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
IT1223799B (it) Forma di dosaggio per la somministrazione di diltiazem
IT8348294A0 (it) Composti e composizioni per il trattamento delle affezioni cardiocircolatorie e procedimento di preparazione
IT8720181A0 (it) Composizioni farmaceutiche contenenti alcoli superiori per il trattamento di patologie della prostata.
PT87642A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors
FI902653A0 (fi) Valmiste hampaiden hoitamiseksi sekä valmisteen valmistus
IT1173725B (it) Composizione terapeutica a base di acido 5-idrossi-decanoico o suoi de rivati,per il trattamento di malattie cardiovascolari
IT1210935B (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
IT8050185A0 (it) Apparecchio per il trattamento di pavimenti
IT1159815B (it) Composizione medicinale per il trattamento di certe neurovirosi
IT1224741B (it) Dispositivo per il trattamento delle malattie delle gengive
IT8720034A0 (it) Composizioni farmaceutiche per il trattamento di sindromi psico-organiche cerebrali.
IT1154276B (it) Composti piridinici per il trattamento di cardiopatie coronariche
IT8821369A0 (it) Composizione farmaceutica utile per il trattamento di malattie cardiovascolari.
IT8419940A0 (it) Nuovi medicinali per il trattamento di malattie cardiache.
IT8248329A0 (it) Tienil e benzotienil-terz.-butilamminofenossipropanoli per il trattamento di affezioni cardiovascolari
KR890701106A (ko) 과지혈증의 치료를 위한 옥소퀴나졸린 유도체의 용도
IT8219330A0 (it) Composto medicinale per il trattamento di malattie di cuore.
DE3366025D1 (en) Medicine for the treatment of the neoplazic disease
IT1212555B (it) Composizione a base di dobesilato di calcio per il trattamento di malattie cardiache
IT8848258A0 (it) Composizione farmaceutica per il trattamento delle affezioni parodontali
DK681288D0 (da) Aenootropt terapeutisk laegemiddelae
DK486483D0 (da) Medicinspray med dosistaeller

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970925